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Abstract 
Objective: To investigate the effectiveness of combining mirtazapine with Serotonin-
Noradrenaline Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitor (SSRI) 
antidepressants for patients in primary care who had not responded to an antidepressant. 
Design:  A two parallel-group multi-centre, placebo controlled, randomised trial comparing 
the addition of mirtazapine to placebo for patients who had been adherent to an SSRI or 
SNRI for at least 6 weeks and were still depressed. Participants were stratified by centre and 
minimised by baseline Beck Depression Inventory score [BDI-II], gender and current 
psychological therapy. Participants, their General Practitioners (GPs), and the research team 
were blind to the allocation. Primary analyses compared the two groups as allocated without 
imputing missing data Setting: 106 general practices in 4 centres in the UK; Bristol, Exeter, 
Hull and North Staffordshire. 
Participants: Between August 2013 and October 2015, we recruited 480 participants aged 
over 17 years, 69.1% of whom were female. Participants scored >13 using the BDI-II and 
fulfilled International Classification of Diseases [ICD]-10 criteria for depression. Exclusion 
criteria included bipolar disorder, psychosis and major alcohol/substance abuse. 431 (89.8%) 
were included in the (primary) 12-week follow-up.  
Intervention: 241 participants were randomised to mirtazapine and 239 to placebo, both 
given in addition to their usual SSRI/SNRI medication. They were followed up at 12, 24 and 
52 weeks.  
Main outcome measures: Depressive symptoms at 12 weeks post-randomisation, measured 
using the BDI-II score as a continuous variable. Secondary outcomes include measures of 
anxiety, quality of life and adverse effects at 12, 24 and 52 weeks.  
Results: BDI-II scores at 12 weeks were lower in the mirtazapine group after adjustment for 
baseline BDI-II and minimisation/stratification variables, although the confidence interval 
included the null (mean (SD) BDI-II scores at 12 weeks: 18.0 (12.3) in the mirtazapine 
group; 19.7 (12.4) in the placebo group; adjusted difference between means -1.83 (95% 
confidence interval: -3.92 to 0.27, p=0.087)). Adverse effects were more frequent in the 
mirtazapine group and associated with stopping the trial medication. 
Conclusion: This study did not find evidence of a clinically important benefit for mirtazapine 
in addition to an SSRI or SNRI antidepressant over placebo in a treatment resistant group of 
primary care patients with depression. This remains an area of important unmet need where 
there is limited evidence of effective treatment options.  
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Trial registration: This trial is registered ISRCTN 06653773. 
 
Funding: National Institute for Health Research Health Technology Assessment 11/129/76 
 
Introduction 
Depression is among the top five contributors to the global burden of disease, and by 2030 is 
predicted to be the leading cause of disability in high income countries(1). People with 
depression are usually managed in primary care in the UK, and antidepressants are often the 
first-line treatment. The number of prescriptions for antidepressants has risen dramatically in 
recent years in the NHS, increasing by 6.8% (3.9 million items) between 2014 and 2015 (total 
61million items)(2). However, many patients do not respond to antidepressants. The 
STAR*D study (Sequenced Treatment Alternatives to Relieve Depression) found that half of 
those treated did not experience at least a 50% reduction in depressive symptoms following 
12-14 weeks of treatment with a single antidepressant(3). A substantial proportion of those 
who take their antidepressants in an adequate dose and for an adequate period, do not 
experience a clinically meaningful improvement in their depressive symptoms.  
 
The National Institute for Health and Care Excellence (NICE) advises general practitioners 
(GPs) to reconsider treatment if there has been no response after 4 to 6 weeks of 
antidepressant medication(4). There is currently limited evidence to guide GPs in the 
management of patients who meet the International Classification of Diseases (ICD-10) 
criteria for depression after taking an SSRI or SNRI antidepressant at an adequate dose for a 
minimum of six weeks(5). Several pharmacological strategies have been proposed, including 
increasing the dose, switching antidepressants, combining two antidepressants and 
augmenting the antidepressant with another psychotropic drug, for example lithium or an 
antipsychotic. (6). A systematic review of antidepressant combinations for those who did not 
respond to a single drug found that the small number of trials and methodological drawbacks 
of those trials precluded definitive conclusions about effectiveness and some of the 
combinations carry substantial risk of adverse effects and are not considered appropriate for 
initiation in primary care (7). There is a pharmacological rationale for adding a second 
antidepressant with a different and complementary mode of action to SSRIs or SNRIs. 
Mirtazapine, a noradrenaline (alpha2-adrenoreceptor) and serotonin (5HT-2 and 5HT-3) 
antagonist, has the potential for an additive and perhaps synergistic action with SSRIs and 
SNRIs and could enhance clinical response compared to monotherapy with SSRIs or SNRIs. 
There have been four trials of this combination against SSRI/SNRI monotherapy in both 
treatment resistant participants and in those without treatment failure, with mixed results (8-
11).  
 
The aim of this study was to determine the effectiveness of adding mirtazapine to an SSRI or 
SNRI in reducing depressive symptoms and improving quality of life at 12 weeks (primary 
follow-up), 24 and 52 weeks, compared with adding placebo for patients in primary care who 
are still depressed after an adequate course of treatment.  
 
Methods 
Study design and participants 
The MIR Study was a two-parallel group multi-centre pragmatic placebo controlled 
randomised trial with allocation at the level of the individual. Participants were recruited from 
general practices in areas surrounding the four centres of Bristol, Exeter, Hull and 
Keele/North Staffs.  Eligible participants were: over 17 years; currently taking an SSRI or 
SNRI antidepressant at an adequate dose, had done so for at least six weeks and had adhered 
to their medication; had a Beck Depression Inventory, 2nd version (BDI-II) score of at least 
14(12); and fulfilled ICD-10 criteria for depression. We excluded patients with bipolar 
disorder, psychosis or major alcohol/substance abuse, a diagnosis of dementia, those who 
were unable to complete the questionnaires, and women who were pregnant, breast feeding, 
or planning pregnancy. 
 
A three-stage recruitment process was used to identify potential participants. General 
practices searched their computerised records to identify patients who had received repeated 
prescriptions for an antidepressant during the previous 4 months and who were being 
prescribed an antidepressant at an adequate dose. GPs screened this list of patients and 
excluded patients based on study eligibility criteria. A letter of invitation and brief 
information about the study was sent to the potentially eligible participants, seeking 
permission for the research team to contact them. GPs could also invite patients to take part 
in the study during a consultation, in which case the GP provided the patient with information 
about the study and obtained permission to pass contact details to the research team. Those 
who agreed to be contacted were sent a postal questionnaire. This included questions about 
their depressive symptoms (BDI-II) and use of antidepressants. 
Those who met the initial criteria of severity of depressive symptoms and adherence to an 
adequate dose of an antidepressant for at least six weeks were contacted by a researcher by 
telephone to ascertain their eligibility. Face to face baseline assessments were then conducted 
in the participants’ own homes, at their GP surgeries or at nearby NHS/University premises. 
Only those patients who fulfilled ICD-10 criteria (category F32) for their current depressive 
episode (assessed using the revised Clinical Interview Schedule)(13), had a BDI-II score of 
≥14 and who were continuing to take the prescribed antidepressants at an adequate dose were 
eligible to participate in the trial.  
 
Randomisation and Masking 
 
Those who were eligible and gave written informed consent were randomised to one of two 
treatments: (i) one × 15mg encapsulated mirtazapine daily for 2 weeks followed by two × 
15mg encapsulated mirtazapine for up to 50 weeks; or (ii) identical placebo.  
Randomisation was by means of a computer-generated code, ensuring that allocation was 
concealed from the recruiting researcher. Randomisation was stratified by centre and 
minimised on baseline BDI-II score (mild <26; moderate 26–34; severe ≥ 35), gender 
(male/female), and current receipt of psychological services (yes/no).  
 
The labelling of medication packs was Medicines and Healthcare Products Regulatory 
Authority (MHRA) approved. Each medication pack had an identification number, randomly 
generated to ensure mirtazapine and placebo medicine packs were indistinguishable to 
maintain allocation concealment. The random numbers were generated by the Bristol 
Randomised Trials Collaboration and provided to the manufacturer. Participants and GPs 
were advised to use with caution other serotonergic drugs such as tramadol or the triptan 
group of drugs.  
 
Participants were free to stop taking the study medication at any time. Participants, clinicians, 
outcome assessors and the research team were blinded to allocation. After the primary 
follow-up at 12 weeks, participants were offered the opportunity to be unblinded or to remain 
blind to allocation This was not in the original protocol but was required by the Research 
Ethics Committee to ensure that those who had not improved had the option of reviewing 
their treatment. Those who elected to be unblinded no longer received the trial medication, 
but outcome measures continued to be collected. All participants continued with their GP 
care and usual antidepressants. Clinicians were not restricted in referring their patients to 
psychological services. 
 
Procedures  
 
Participants were followed up at 6 weeks, 12 weeks, 24 weeks and 52 weeks. To maximise 
response rates, follow-up assessments at 12, 24 and 52 weeks were conducted at a face-to-
face appointment with a researcher. If this was not possible then questionnaires were posted 
or administered over the phone.  
 
The primary outcome was BDI-II score at 12 weeks post-randomisation, measured as 
continuous variable, adjusted for baseline. We aimed to recruit 200 participants in each 
group, giving 91% power to detect a difference of 0.33 standard deviations at a two-sided 5% 
significance level. This would be equivalent to 3-4 points on the BDI-II, reported to be a 
clinically important difference(14). Allowing for 15% loss to follow-up at 12 weeks, we 
planned to recruit 472 participants. 
 
Secondary outcomes were: ‘response’ defined as at least a 50% reduction in BDI-II score 
compared with baseline; ‘remission’, defined as a score on the BDI-II of less than 10; Patient 
Health Questionnaire (PHQ-9) (15), a brief depression measure included because it is widely 
used in primary care: anxiety symptoms measured with GAD-7(16); and adverse effects 
using the Antidepressant Side Effect Checklist (ASEC)(17); quality of life measured using 
the EQ-5D-5L(18); social and physical functioning using the SF-12(19); and adherence to 
antidepressants using a  4-item self-report measure(20). All these secondary outcomes were 
measured at 12, 24 (excluding ASEC) and 52 weeks, and again adjustments for baseline 
scores were made where appropriate. Cost effectiveness data will be presented in a separate 
publication.  
 
 
 
 
 Statistical Analysis 
 
Analysis and reporting were in line with CONSORT(21) guidelines based on a pre-specified 
statistical analysis plan (SAP) approved by the Trial Steering Committee (22). Primary 
analyses were conducted comparing the two groups as randomised, without imputing missing 
values. Depending on the nature of the outcome variable (continuous or binary), linear or 
logistic regression models were used to compare the groups as randomised, adjusting for 
stratification and minimisation variables and (where available) the corresponding baseline 
value. 
 
Secondary analyses of the primary and all secondary outcomes included additional 
adjustment for variables demonstrating marked imbalance at baseline (ascertained using 
descriptive statistics). 
 
In all analyses we present regression coefficients (or odds ratios for binary outcomes), with 
95% confidence intervals and p-values. Effect sizes are presented for the BDI-II outcomes 
and are calculated based on Cohen’s d statistic. 
 
We conducted pre-specified subgroup analyses by introducing appropriate interaction terms 
into the regression models, to investigate differential effects according to: baseline depression 
severity (BDI-II); and a multi-level measure of degree of treatment resistance based on 
duration of symptoms and prior treatment with antidepressants. This latter variable was 
categorised as: not prescribed anti-depressants in the past; prescribed anti-depressants in the 
past and depressed for less than 1 year; prescribed anti-depressants in the past and depressed 
for 1-2 years; prescribed anti-depressants in the past and depressed for more than 2 years. 
 
Sensitivity analyses were conducted to assess the robustness of our primary analysis. These 
included per protocol analyses of the primary outcome at 12 and 52 weeks and, since these 
were likely to be biased, a Complier Average Causal Effect (CACE) analysis at 12, 24 and 
52(23). In this analysis ‘compliers’ were defined as those who had continued taking their trial 
medication up until 12 weeks. An additional sensitivity analysis at 24 and 52 weeks 
examined between-group differences in BDI-II score in those who remained blinded 
throughout the trial. We also investigated the influence of missing data by performing 
analyses of the primary outcome under different assumptions: “best” and “worst” case 
scenarios (representing the lowest and highest possible BDI-II scores) and multiple 
imputation by chained equation (MICE) to impute missing data(24). When using MICE, 25 
datasets were generated, and 10 switching procedures were undertaken. The imputation 
model included all variables predictive of missingness as well as all the variables used in the 
primary analysis. 
Analyses were performed using Stata v14.(25) 
 
Role of the funding source 
 
The funding source had no role in study design, data collection, data analysis, interpretation 
of data or writing of the report. The corresponding author had full access to all the data in the 
study and had final responsibility for the decision to submit for publication. 
 
Results 
The screening process commenced on the 1st of August 2013, and the final patient was 
randomised to the trial on 6th October 2015. All follow-up data were collected between 
August 2015 and the end of October 2016.We identified 856 patients as potentially eligible 
and invited them to attend a baseline appointment, but 105 (12%) declined. Those who 
declined were comparable to attenders on age, sex and home ownership, but less likely to be 
educated to A-level or above (31% vs 48%). At baseline, one patient was eligible but 
declined, one was alcohol-dependent, one had recently had their dose of antidepressant 
altered and 268 did not satisfy the ICD-10 criteria for a major depressive episode and/or had a 
BD-II score of <14 A total of 480 participants were randomised (mirtazapine and 
SSRI/SNRI: n=241; placebo and SSRI/SNRI n=239); 431 (89.8%) were followed up at 12 
weeks, 403 (84.0%) at 24 weeks and 390 (81.3%) at 52 weeks (figure).  
 
The two groups were similar in baseline characteristics, but there was some evidence that 
participants in the mirtazapine group had more severe depression (Table 1). Participants 
randomised to mirtazapine were more likely to have a prior history of depression, and a 
higher proportion had had suicidal thoughts in the past.  
 
 
 
Table 1: Baseline characteristics of randomised participants 
 
Allocated groups 
Mirtazapine + 
SSRI/SNRI 
(n=241) 
Placebo + 
SSRI/SNRI 
(n=239) 
Stratification variable 
Centre: n(%) Bristol 89 36.9% 88 36.8% 
Exeter 61 25.3% 61 25.5% 
Keele/North Staffs 41 17.0% 41 17.2% 
Hull 50 20.7% 49 20.5% 
Minimisation variables 
Female: n(%) 168 69.7% 164 68.6% 
Baseline BDI-II: n(%) 14-25 77 32.0% 79 33.1% 
26-34 78 32.4% 78 32.6% 
>=35 86 35.7% 82 34.3% 
Currently receiving psychological services: n(%) 33 13.7% 29 12.1% 
Socio-demographic variables 
Age (years): mean (SD) 50.4 13.8 49.9 12.5 
Ethnic group: n(%) White 233 96.7% 235 98.3% 
Non-white 
 
 
8 
 
 
2.3% 
 
 
4 
 
 
1.7% 
 
 
Marital status: n(%) Married/Living as married 142 58.9% 135 56.5% 
Single 47 19.5% 53 22.2% 
Separated/Divorced/ 
Widowed 52 21.6% 51 21.3% 
Employment status: 
n(%) Not working 
 
132 
 
54.8% 
 
104 
 
43.5% 
 
Educational 
attainment: n(%) 
A-level or higher 115 47.7% 115 48.1% 
GSCE; Standard Grade; O-
level or equivalent 72 29.9% 78 32.6% 
No formal qualification 54 22.4% 46 19.2% 
Financial wellbeing: 
n(%)  
Just about getting by or 
worse 
 
130 
 
53.9% 
 
126 
 
52.7% 
Alcohol use score*: median (IQR) 
2.0 
(1.0, 
4.0) 2.0 
(1.0, 
4.0) 
Number of life events in the past 6 months: mean 
(SD) 1.0 1.0 1.1 1.0 
Social support score: mean (SD) 12.2 4.1 12.8 4.0 
Caring responsibilities 
Providing care for someone who is disabled; n(%) 30 12.4% 37 15.5% 
Measures of depression 
Suffered from depression in the past: n(%) 206 85.5% 190 79.5% 
Previous referral to a psychiatrist for depression: 
n(%)a 71 34.5% 60 31.6% 
Number of prior 
episodes of 
depression: n(%)b 
None 3 1.5% 5 2.6% 
One 14 6.8% 8 4.2% 
Two to four 82 39.8% 79 41.6% 
Five or more 107 51.9% 98 51.6% 
Length of current 
course of 
antidepressants: n(%) 
<6 months  26 10.8% 20 8.4% 
6 or more months  215 89.2% 219 91.6% 
ICD-10 primary 
diagnosis: n(%) 
Mild 38 15.8% 44 18.4% 
Moderate 138 57.3% 144 60.3% 
Severe 65 27.0% 51 21.3% 
CIS-R score: mean (SD) 28.3 8.2 27.0 8.3 
BDI-II score: mean (SD) 31.5 10.2 30.6 9.6 
GAD-7 score: mean (SD)c 11.3 4.8 10.7 4.8 
PHQ-9 score: mean (SD) 16.7 5.5 16.0 5.5 
EQ-5D-5L score: mean (SD)d 0.65 0.26 0.69 0.22 
SF-12 aggregate physical functioning score: mean 
(SD)e 45.7 13.8 46.4 13.1 
SF-12 aggregate mental functioning score: mean 
(SD)e 27.9 9.6 29.2 9.7 
Suicidal ideation (CIS-
R thoughts/plans): 
n(%) 
No suicidal thoughts 81 33.6% 119 49.8% 
Patient feels life isn't worth 
living 59 24.5% 44 18.4% 
Suicidal thoughts/Plans 101 41.9% 76 31.8% 
 Note: Number of missing observations by treatment group:  
 a n=35 mirtazapine, n=49 placebo;b n=35 mirtazapine,  n=49 placebo; c n=3 mirtazapine, 
n=0 placebo; d n=1 mirtazapine, n=1 placebo;e n=7 mirtazapine, n=4 placebo 
*AUDIT score (26) 
 
At 12 weeks, the mean BDI-II score in those randomised to the usual care and mirtazapine 
group was 18.0 (SD=12.3) compared with 19.7 (SD=12.4) in those randomised to usual care 
and placebo (Table 2). There was a small difference in favour of the intervention after 
adjustment for baseline BDI-II score and the stratification and minimisation variables, centre, 
baseline BDI-II score tertiles, gender and whether the patient was receiving psychological 
therapy at baseline. The confidence interval (CI) included the null; it is therefore possible that 
there was no difference between the two treatment groups (adjusted difference in means = -
1.83 (95% CI -3.92 to 0.27, p=0.087); Table 2). Slightly larger differences were observed in a 
per protocol and CACE analyses (Table A1). Further adjustment for characteristics showing 
an imbalance at baseline did not materially affect the results of the primary analysis (Table 
A2).  
 
At 24 and 52 weeks, the adjusted difference in BDI-II between the two groups was smaller 
and again included the null (24 weeks: adjusted difference in means = -0.85 (95% CI -3.12 to 
1.43); 52 weeks: adjusted difference in means = 0.17 (95% CI -2.13 to 2.46)) (Table 2). 
Adopting per protocol and CACE approaches to analysis of these outcomes yielded similar or 
slightly larger differences (Table A1). 
 
Table 2: Means and difference in mean BDI-II scores between treatment groups at 12, 24 and 
52 weeks 
 Mirtazapine + 
SSRI/SNRI 
Placebo + 
SSRI/SNRI 
Comparison 
 N Mean (SD) N Mean (SD) Adjusted* 
difference in means 
(95% CI) 
p-value Effect 
size 
(Cohen’s 
d) 
Baseline 241 31.5 (10.2) 239 30.6 (9.6) - - - 
Primary outcome 
12 weeks 214 18.0 (12.3) 217 19.7 (12.4) -1.83 (-3.92 to 0.27) 0.09 0.148 
Secondary outcomes 
24 weeks 196 17.3 (12.9) 206 18.2 (12.6) -0.85 (-3.12 to 1.43) 0.46 0.066 
52 weeks 190 16.8 (12.7) 198 16.7 (12.2) 0.17 (-2.13 to 2.46) 0.89 0.014 
*: adjusted for baseline BDI-II score and the stratification and other minimisation variables 
 
Participants were able to request unblinding after the primary outcome at 12 weeks. The 
results in table 2 at 24 and 52 weeks include all those who remained in the trial, whether they 
were unblinded or not. In the mirtazapine group 83 individuals requested unblinding by 52 
weeks, and 103 individuals in the placebo group. A sensitivity analysis at 24 and 52 weeks 
found no between-group differences in BDI-II score amongst those who remained blinded 
throughout the trial (Table A3). 
 
The between-group differences in all the secondary outcome scores at 12 weeks were in 
favour of the intervention, including a second measure of depressive symptoms, the PHQ 
-9. However, the differences were small and, in almost every case (apart from the GAD-7, 
which measures anxiety symptoms, and the mental health component of the SF-12) the CI for 
the difference included the null (Table 3). Adherence to the trial medication was substantially 
lower in the intervention group compared with placebo (Table 3). Outcomes at later time 
points showed smaller between-group differences (Table A4).  
 
Table 3: Secondary outcomes at 12 weeks 
 Mirtazapine + 
SSRI/SNRI 
Placebo + SSRI/SNRI Comparison 
 N N (%) Mean 
(SD) 
N N (%) Mean 
(SD) 
Adjusted OR* 
(95% CI) 
Adjusted* 
difference in 
means (95% 
CI) 
p-
value 
12 weeks 
“Response” 214 94 
(43.9) 
- 217 78 
(35.9) 
- 1.39 (0.94 to 
2.07) 
- 0.099 
“Remission” 214 63 
(29.4) 
- 217 53 
(24.4) 
- 1.29 (0.82 to 
2.02) 
- 0.266 
GAD-7 214 - 7.15 
(5.63) 
217 - 7.89 
(5.78) 
- -0.98 (-1.93 to 
-0.03) 
0.044 
EQ-5D-5L 213 - 0.72 
(0.27) 
216 - 0.73 
(0.25) 
- 0.01 (-0.02 to 
0.05) 
0.400 
SF-12 
(physical) 
208 - 44.09 
(12.87) 
210 - 45.85 
(12.54) 
- -1.09 (-2.75 to 
0.57) 
0.196 
SF-12 
(mental) 
208 - 39.94 
(12.27) 
210 - 36.33 
(12.53) 
- 3.91 (1.63 to 
6.20) 
0.001 
PHQ-9 212 - 9.74 
(6.35) 
217 - 10.63 
(6.21) 
- -1.05 (-2.14 to 
0.04) 
0.058 
Adherence 210 156 
(74.3) 
- 214 180 
(84.1) 
- 0.55 (0.34 to 
0.89) 
- 0.015 
ASEC 184 - 10.13 
(7.02) 
206 - 9.77 
(7.93) 
- 0.35 (-1.04 to 
1.73) 
0.624 
 
* Adjusted for baseline values of the outcome and stratification and minimisation variables 
except in the case of adherence at 12 weeks where adjustment was made solely for 
stratification and minimisation variables 
 
There was no between-group difference in adverse effects using the ASEC at 12 weeks 
(Table 3). We also collected spontaneous participant reports of adverse effects. In the first 12 
weeks most reported adverse effects were minor. There were 11 Serious Adverse Events 
resulting in hospitalisation, eight of which occurred in the intervention group (Table A5). 
More patients in the intervention group reported non-serious adverse effects, and 46 
participants reporting adverse effects in this group stopped their medication compared to 9 in 
the placebo group (Table 4).  
 
Table 4: Most frequent types and most common examples of adverse events spontaneously 
reported by participants in the 12 weeks from randomisation* 
 Mirtazapine + SSRI/SNRI (n=241) Placebo + SSRI/SNRI (n=239) 
 Number of 
patients 
reporting AE 
(% of patients 
randomised 
reporting AE) 
Number of 
patients 
reporting AE 
who stopped 
IMP  
Number of 
patients 
reporting AE 
(% of patients 
randomised 
reporting AE) 
Number of 
patients 
reporting AE 
who stopped 
IMP  
Anti-cholinergic 
Dry mouth, 
blurred vision 
or urinary 
difficulties 
16 (6.6%) 3  4 (1.7%) 0 
Central Nervous 
System 
Drowsiness, 
feeling light 
headed, 
headache and 
unpleasant 
dreams 
59 (24.5%) 23  20 (8.4%) 2  
Increase in 
appetite/weight 
gain 
26 (10.8%) 7  8 (3.3%) 0 
Psychiatric 
Increase in 
anxiety 
8 (3.3%) 4  5 (2.1%) 0 
 Other: 
Restless legs 
 nausea and 
peripheral 
oedema 
47 (19.5%) 13  47 (19.7%) 8 
Any  121 (50.2%) 46 71 (29.7%) 9 
* Patients may have reported more than one type of adverse event therefore column totals are 
greater than the total number of individuals reporting adverse effects 
 
We compared our analyses of the primary outcome using complete cases with analyses that 
addressed missing data. The findings using complete cases appeared to be robust to various 
assumptions regarding missing data (Table A6). 
  
Regarding the two pre-planned subgroup analyses, we found no evidence that either had any 
effect on the difference between the mirtazapine and placebo groups (p-value for interaction 
with treatment group for baseline depression severity: p=0.101; p-value for interaction with 
treatment group for treatment resistance: p=0.30). 
 
Discussion  
Statement of principal findings 
This study did not find convincing evidence of a clinically important benefit for mirtazapine 
over placebo when given in addition to an SSRI or SNRI antidepressant for patients who had 
remained depressed after at least 6 weeks of an antidepressant, recruited from primary care.  
In the primary analysis at 12 weeks, the placebo group improved from a baseline BDI-II 
score of 30.6 to a mean of 19.7 and the intervention group from a baseline BDI-II score of 
31.5 to a mean of 18.0. We based our sample size calculation on detecting a between group 
difference equivalent to 3 to 4 BDI-II points, which we posited would be clinically important. 
The adjusted difference (in means) between the groups after 12 weeks was less than this at  
-1.83 (95% CI; -3.92 to 0.27, p=0.087) points on the BDI-II in favour of the intervention 
group. Despite the fact that the lower limit of the 95% confidence interval for this difference 
includes the possibility of a clinically meaningful effect, the CI also includes the null and the 
most likely (mean) effect is small, making clinical benefit unlikely. 
Similar observations of small differences between the treatment groups in favour of the 
mirtazapine group were observed for the secondary outcomes at 12 weeks, but for most 
outcomes the 95% confidence intervals surrounding the difference between groups included 
the null. This weak evidence of a small effect at 12 weeks is supported by changes in favour 
of the intervention group in the SF-12 aggregate mental health score (between-group 
difference 3.91 (95% CI 1.63 to 6.20)) and GAD-7 (between-group difference -0.98 (95%CI -
1.93 to -0.03)) where confidence intervals did not include the null, although the clinical 
importance of these small differences is not clear.  Outcomes at later time points showed 
smaller between-group differences with no evidence of benefit over the longer term. CACE 
and per protocol analyses for the primary outcome, designed to estimate treatment effects in 
those who complied with their allocated treatment, showed slightly larger between group 
differences than the primary analyses but these were still consistent with a chance 
observation, and per-protocol analyses are known to be biased. Pre-specified subgroup 
analyses based on severity and degree of treatment resistance did not yield any evidence of 
effect modification.  
 
In the mirtazapine group 46 participants who reported adverse effects stopped their 
medication, compared with nine in the placebo group. Adherence was therefore substantially 
lower in the mirtazapine group compared with placebo and is likely to have been a 
consequence of adverse effects. Whilst there was no difference between the two groups in 
their rating of adverse effects using the ASEC scale, this may be in part due to the lower rate 
of adherence to the trial medication in the intervention group. The number of SAEs was small 
in both groups and none were directly attributable to the intervention.   
 
Strengths and weaknesses of the study 
Participants, investigators and assessors were all blind to the allocation up to and including 
the primary outcome at 12 weeks. Follow-up rates throughout the trial were good at all sites, 
with the overall follow-up rates of 90% at 12 weeks, 84% at 24 weeks and 81% at 52 weeks. 
Sensitivity analyses were conducted to assess the impact of missing data on the analysis of 
the primary outcome. Whether estimating the missing data assuming a “best” or “worst” case 
scenario or using multiple imputation, the observed difference in BDI-II scores at 12 weeks 
between treatment groups was small. There were some minor baseline imbalances between 
the two groups but adjustment for these did not materially affect the outcome of the trial 
results.  
 The criteria for defining inadequate response to treatment that we adopted have been used 
elsewhere in primary care research(27) and were designed to be inclusive while reflecting 
NICE treatment guidelines(4). Our approach accords with the Maudsley staging method 
where treatment failure following an adequate dose of an antidepressant for 6 weeks is an 
important starting point on a continuum of treatment failure (28). The authors also point out 
that in addition to treatment failure, severity and duration of depression are also important 
dimensions of treatment resistance. Nearly all (90%) of our participants had been taking an 
antidepressant for at least six months and the range of symptom severity in our sample was 
evenly spread between 3 terciles; mild to moderate, moderate to severe and severe. In 
addition most participants reported previous episodes of depression. Hence the population 
recruited to the study is representative of the group for whom there is uncertainty around 
ongoing management in primary care. 
 
We based our view of the minimal clinically important difference (MCID) between 
intervention and placebo groups of 3-4 points in BDI-II score on previous recommendations 
from NICE(4). Since our protocol was written an approach towards establishing MCID using 
self-rated global ratings of improvement has been developed(14). This approach gives an 
estimate of an MCID in depression of 17.5% reduction in BDI-II score for a depressed 
primary care population, but suggests that the MCID is higher, at 32% in a non-responsive 
population similar to that studied here. This translates to BDI-II differences of 3.5 and 5.9 
BDI-II points respectively. It therefore seems unlikely that mirtazapine would provide a 
clinically important benefit, although there is still considerable uncertainty around the 
clinically important difference in treatment outcome for this group of patients.  
 
Comparison to other studies 
Two earlier small studies in patients, one of which was in treatment resistant patients (8), and 
one in those who had not failed previous treatment(9) reported that mirtazapine in 
combination with an SSRI gave a greater improvement than monotherapy. A further recent 
study also reported benefit in non-resistant patients and that it was well tolerated in 
combination with either an SSRI or venlafaxine (an SNRI) (10). The STAR*D study(3) 
compared venlafaxine plus mirtazapine, to tranylcypromine, a MAOI antidepressant. 
Although there was a modest advantage for the combination of venlafaxine and mirtazapine 
over the MAOI, there was no placebo group in this comparison. The large CO-MED 
randomised trial compared the combination of venlafaxine and mirtazapine to escitalopram 
(an SSRI) and placebo in patients who had either recurrent depression or chronic depression 
lasting at least 2 years(11). There was no difference in response rates between the two groups 
but the burden of adverse effects was greater in the combined antidepressant group. Those 
recruited into CO-MED differ from our study population in that they were not necessarily 
taking an antidepressant at baseline.  
 
Conclusion and unanswered questions 
Half of those who take antidepressants in an adequate dose for an adequate duration remain 
depressed(3, 29). This represents a substantial burden of illness and an unmet or inadequately 
met need. Although many patients in this group can benefit from CBT, it is not always easily 
available, nor is it universally effective (27). In primary care, where most initial encounters 
between people with depression and clinicians take place, antidepressants are still very 
widely prescribed and remain a first line treatment. Several pharmacological strategies have 
been developed to help those who do not respond to first line treatment, bu the evidence 
supporting them is not of very high quality(6). There is therefore a lack of clear guidance for 
clinicians in an area of unmet need, and this is particularly important in primary care because 
of the size of the population that does not improve on antidepressants (29). The lack of clear 
evidence of benefit in our study, combined with the increased burden of adverse effects in the 
mirtazapine group, means that we cannot recommend this combination as a routine strategy 
in primary care for those who remain depressed after adequate treatment with SSRI/SNRI 
antidepressants.  
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Allocated to SSRI or SNRI + Mirtazapine (n=241) 
 
11 not followed up  
    2 withdrew from study 
    9 lost to follow up 
 
Randomised (n=480) 
Allocated to SSRI or SNRI + Placebo (n=239) 
 
12 not followed up  
    3 withdrew from study 
    9 lost to follow up 
     
 Patients reached 6 weeks (n=227) 
221 returned questionnaire 
221 completed BDI-II 
 
  
  
  
Patients reached 6 weeks (n=230) 
219 returned questionnaire 
217 completed BDI-II 
 
  
  
  
21 not followed up 
    3 withdrew from study  
    18 lost to follow up 
15 not followed up 
    5 withdrew from study 
    10 lost to follow-up  
Patients reached 12 weeks (n=224) 
217 returned questionnaire and completed BDI-
II; included in intention to treat analysis without 
imputation of missing data 
 
  
  
Patients reached 12 weeks (n=220) 
214 returned questionnaire and completed BDI-
II; included in intention to treat analysis without 
imputation of missing data 
 
  
  
  
23 not followed up 
   8 withdrew from study 
   15 lost to follow-up  
32 not followed up 
    4 withdrew from study  
    28 lost to follow up 
Patients reached 24 weeks (n=216) 
207 returned questionnaire 
206 completed BDI-II 
  
  
  
Patients reached 24 weeks (n=209) 
196 returned questionnaire 
196 completed BDI-II 
 
 
  
  
  
40 not followed up 
    12 withdrew from study 
    28 lost to follow-up 
  
50 not followed up  
    6 withdrew from study 
    44 lost to follow up 
Patients reached 52 weeks (n=199) 
199 returned questionnaire 
198 completed BDI-II 
 
  
  
  
Patients reached 52 weeks (n=191) 
191 returned questionnaire 
190 completed BDI-II 
 
 
  
Attended a baseline interview (n=751) 
Randomised (n=480) 
271 excluded 
270 ineligible 
  1 Eligible but declined  
  
Eligible for baseline assessment (n=856) 
Randomised (n=480) 
Declined to take part in baseline assessment 
(n= 105)  
Appendix 
 
Table A1 Per protocol and CACE analyses of BDI-II scores 
 Number of 
patients in 
model 
Difference in 
means* 
 95% CI p-value 
 CACE 
12 weeks 427 -2.39  -5.18 to 0.40 0.093 
24 weeks 396 -1.02  -3.04 to 1.90 0.494 
12 months 379 0.17  -2.91 to 3.25 0.914 
 Per protocol 
12 weeks 327 -2.18  -4.60 to 0.24 0.077 
12 months 138 -1.08  -5.11 to 2.95 0.598 
* Adjusted for baseline BDI-II score, stratification and minimisation variables  
 
 
Table A2: Means and differences in mean BDI-II scores at 12 weeks, 24 weeks and 12 
months adjusting for baseline BDI-II scores, stratification and other minimisation variables, 
history of depression, length of current course of antidepressants and suicidal ideation 
 Mirtazapine + 
SSRI/SNRI 
Placebo + 
SSRI/SNRI 
Comparison 
 N Mean (SD) N Mean (SD) Adjusted difference in means 
(95% CI) 
p-value 
Primary outcome 
12 weeks 214 18.0 (12.3) 217 19.7 (12.4) -2.12 (-4.25 to 0.02) 0.052 
Secondary outcomes 
24 weeks 196 17.3 (12.9) 206 18.2 (12.6) -1.26 (-3.57 to 1.05) 0.28 
12 months 190 16.8 (12.7) 198 16.7 (12.2) -0.29 (-2.61 to 2.03) 0.81 
 
 
 
Table A3: Means and difference in mean BDI-II scores between treatment groups at 24 and 
52 weeks among those remaining blinded* 
 Mirtazapine + 
SSRI/SNRI 
Placebo + 
SSRI/SNRI 
Comparison 
 N Mean (SD) N Mean (SD) Adjusted** 
difference in means 
(95% CI) 
p-value 
24 weeks *** 152 17.4 (13.0) 141 17.0 (12.7) 0.26 (-2.41 to 2.94) 0.846 
52 weeks *** 120 16.5 (13.1) 110 15.1 (11.4) 1.48 (-1.57 to 4.53) 0.341 
*This is a post-hoc exploratory analysis and was not part of the original SAP 
**: adjusted for baseline BDI-II score and the stratification and other minimisation variables 
***: One patient in the placebo group returned a 24-week questionnaire without a BDI-II 
measure as did one patient in the mirtazapine group at 52 weeks 
 
Table A4: Secondary outcomes at 24 weeks and 12 months (except BDI-II) 
 Mirtazapine + 
SSRI/SNRI 
Placebo + SSRI/SNRI Comparison 
 N N (%) Mean 
(SD) 
N N (%) Mean 
(SD) 
Adjusted OR* 
(95% CI) 
Adjusted* 
difference in 
means  (95% 
CI) 
p-
value 
24 weeks 
“Response” 196 96 
(49.0) 
- 206 100 
(48.5) 
- 1.01 (0.67 to 
1.50) 
- 0.977 
“Remission” 196 65 
(33.2) 
- 206 59 
(28.6) 
- 1.28 (0.81 to 
2.01) 
- 0.287 
GAD-7 195 - 6.83 
(5.89) 
206 - 7.17 
(5.86) 
- -0.56 (-1.56 to 
0.44) 
0.274 
EQ-5D-5L 196 - 0.72 
(0.25) 
207 - 0.74 
(0.25) 
- 0.01 (-0.02 to 
0.05) 
0.464 
SF-12 
(physical) 
191 - 42.88 
(13.02) 
201 - 45.37 
(12.75) 
- -1.54 (-3.23 to 
0.15) 
0.075 
SF-12 
(mental) 
191 - 39.89 
(13.92) 
201 - 37.91 
(12.43) 
- 2.32 (-0.17 to 
4.80) 
0.068 
 12 months 
“Response” 190 97 
(51.1) 
- 198 101 
(51.0) 
- 0.99 (0.66 to 
1.49) 
- 0.978 
“Remission” 190 63 
(33.2) 
- 198 67 
(33.8) 
- 0.96 (0.62 to 
1.50) 
- 0.873 
GAD-7 189 - 6.81 
(6.23) 
198 - 6.80 
(5.73) 
- -0.17 (-1.23 to 
0.90) 
0.755 
EQ-5D-5L 189 - 0.72 
(0.28) 
199 - 0.75 
(0.25) 
- 0.001 (-0.04 to 
0.04) 
0.950 
SF-12 
(physical) 
182 - 43.34 
(13.42) 
191 - 44.32 
(12.49) 
- -0.47 (-2.19 to 
1.24) 
0.587 
SF-12 
(mental) 
182 - 40.54 
(13.80) 
191 - 39.25 
(13.09) 
- 1.42 (-1.20 to 
4.04) 
0.287 
ASEC 119  9.50 
(7.65) 
136 - 9.59 
(8.26) 
- -0.43 (-2.19 to 
1.33) 
0.630 
* Adjusted for baseline values of the outcome and stratification and minimisation variables 
except in the case of adherence at 12 weeks where adjustment was made solely for 
stratification and minimisation variables 
 
Table A5 Serious Adverse Events in the 12 weeks up to the primary outcome (all requiring 
hospitalisation). 
 
Allocation Brief description of event  Relatedness to IMP as 
rated at follow-up 
Mirtazapine Fall leading to minor injury, 
observed overnight 
Not related  
Mirtazapine Admitted to hospital as a 
day case for pre-planned 
gynaecological procedure 
(D&C).  
Not related  
Mirtazapine Deep Vein Thrombosis Not related  
Mirtazapine Transient Ischaemic Attack Unlikely to be related  
Mirtazapine Dental Extraction Not related  
Mirtazapine Suicidal ideation and self-
harm 
Possibly related 
Mirtazapine Deliberate Overdose Possibly related 
Mirtazapine Pancreatitis (pre-existing 
gallstones) 
Unlikely to be related 
   
Placebo Fall, broken rib. Had not 
started IMP. 
Not related  
Placebo Infective gastroenteritis 
(norovirus) 
Not related  
Placebo Fall leading to Ankle 
fracture 
Not related  
 
In the period following the primary outcome, between 12 and 52 weeks when participants 
could be voluntarily unblinded, there were 36 SAEs, 20 of which occurred in those allocated 
to the Mirtazapine group. None of these were attributable to the IMP.  
 
Table A6: Comparison of results of primary analysis of complete cases with corresponding 
(ITT) analysis where missing data were imputed using “best” and “worst” case scenarios and 
multiple imputation for primary outcome of BDI-II score at 12 weeks 
 N Difference in 
means* 
95% CI p-value 
Complete case 431 -1.83 -3.92 to 0.27 0.087 
“Best” case scenario 480 -2.22 -4.41 to -0.03 0.047 
“Worst” case 
scenario 
480 -1.11 -4.11 to 1.89 0.469 
Multiple imputation 480 -1.78 -3.90 to 0.34 0.100 
* Adjusted for baseline BDI-II score, stratification and minimisation variables 
 
 
 
 
